Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-lin...
Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients ( Dr Arnon Kater - Amsterdam UMC, Amsterdam, Netherlands )
14 Dec 2021
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressi...
Dr Michael Bishop - University of Chicago, Chicago, USA
Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL ( Dr Michael Bishop - University of Chicago, Chicago, USA )
14 Dec 2021
Integrated genomic analysis identifies UBTF tandem duplications as a subtype-def...
Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA
Integrated genomic analysis identifies UBTF tandem duplications as a subtype-defining lesion in paediatric AML ( Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA )
14 Dec 2021
Asciminib found to be safe and effective for heavily pretreated patients with ch...
Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase ( Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA )
14 Dec 2021
Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first ...
Prof Andrew Wei - Monash University, Melbourne, Australia
Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first remission after intensive chemo ( Prof Andrew Wei - Monash University, Melbourne, Australia )
13 Dec 2021
Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL
Dr Ibrahim Aldoss - City of Hope, Duarte, USA
Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL ( Dr Ibrahim Aldoss -  City of Hope, Duarte, USA )
13 Dec 2021
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2021
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes ...
Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, ...
Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups ( Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2021
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory larg...
Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA
Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )
13 Dec 2021
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free ...
Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France
EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs ( Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France )
13 Dec 2021
Real world data supports ciltacabtagene autoleucel as effective option for tripl...
Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Sp...
Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )
12 Dec 2021
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with...
Dr Martin Kaiser - The Institute of Cancer Research, London UK
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London  UK )
12 Dec 2021